Evidence map›Paper›PMID 41617893›Full record

ArticleNature microbiology2026

Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.

Brandon F Keele, Afam A Okoye, Taina T Immonen, Benjamin Varco-Merth, Derick Duell, Candice Nkoy, William Goodwin, Shelby Hoffmeister, Colette M Hughes, Emek Kose and 20 more

Abstract read
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Brandon F Keele *AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-2381-1151
Afam A Okoye *Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Taina T Immonen *AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Benjamin Varco-MerthVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Derick DuellVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Candice NkoyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
William GoodwinVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Shelby HoffmeisterVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Colette M HughesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Emek KoseAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Andrew ConchasAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Charles A GoodmanAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-7968-9466
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Agatha MacairanAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
William J BoscheAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Randy FastAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-3042-9214
Christopher M HomickAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Mike HullAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Kelli OswaldAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Rebecca ShoemakerAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Lorna SilipinoAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Jorden L WelkerAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-3507-5072
Jeremy SmedleyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.ORCID http://orcid.org/0000-0003-3369-4662
Caralyn S LabriolaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-8271-6242
Michael K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-1984-5906
Scott G HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Jacob D EstesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5127-4659
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. jeffrey.lifson@nih.gov.ORCID http://orcid.org/0000-0002-9494-0268
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Sciences University, Portland, OR, USA. pickerl@ohsu.edu.ORCID http://orcid.org/0000-0003-0546-398X

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Bill & Melinda Gates Foundation INV-002377Bill & Melinda Gates Foundation INV-002704Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1AI164560Gates Foundation INV-002377Gates Foundation INV-002704NCI NIH HHS 75N91019D00024NIAID NIH HHS UM1 AI164560NIH HHS 75N91019D00024NIH HHS P51 OD011092
6 · The paper itself

Abstract

The tissue origin(s) and the earliest viral dynamics of HIV rebound after antiretroviral therapy (ART) remain unclear. Here, using barcoded SIVmac239 in rhesus macaques (n = 24), we defined the distribution of barcode-specific viral RNA expression in tissues during ART (n = 6) and then assessed initial clonal rebound 5 and 7 days after ART cessation by identifying barcodes in individual tissues that exceeded the 99th percentile of the on-ART distribution ('outliers'). In 4 of 11 aviraemic and 6 of 7 viraemic animals, 32 such outlier barcodes were identified. Sixteen of these barcodes were also identified in rebound viraemia, confirming specific tissues as rebound origin and early amplification sites. Overall, 27 of the 32 outlier barcodes were determined to reflect rebound origins, of which 96% were in the gastrointestinal tract (26%) or gastrointestinal tract-associated lymphoid tissues (70%). These results indicate that distinct tissue sites differentially support post-ART viral rebound, with potential therapeutic implications for interventions designed to prevent or control these events.

Indexed as

Anti-Retroviral AgentsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsGastrointestinal TractLymphoid TissueMacaca mulattaRNA, ViralViral LoadViremiaAnti-Retroviral AgentsRNA, Viral

Identifiers

PMID41617893
PMCPMC12962976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.